DEDN6526a press release (the promising ADC drug)

[Catherine Poole]

Sadly, I’m hearing that the pharma will not be continuing with this drug research. It has been very promising for so many. Perhaps another company will continue with it.

[lindamg]

Catherine,

That is interesting to hear, and I had been wondering about that. It seems it would be good in a combination trial to provide tumor shrinkage with something like anti-PD-1.

Linda

[Catherine Poole]

So the ADC is back in trial at Sarah Cannon. Here’s the link to their trials:

http://sarahcannonresearch.com/for-patients/search-clinical-trials/melanoma.dot

I had discussions with Genentech and Dr. Infante at ASCO this past June and at the time it looked like it would be discontinued. But got the word a day ago it was back in trial. I hope maybe it will be looked at for a combination drug. It was working well on some patients, including ocular patients.

[rochelle]

Good morning Catherine,

just to chime in on ADC…my oncologist told me recently that she was working on getting an ADC trial up and running @ NYU…she did not say when this trial would launch…but it sounded like sometime in the near future…Dr. Pavlick had been a researcher on ADC and always thought it had potential…and for some of us..ADC could be a viable plan “B”…

Martha

[Catherine Poole]

Hold the optimism: Although Genentech says this is ongoing, clinicaltrials.gov shows it not recruiting but ongoing. I hope to get more answers this week.

[Author]

Posts